vasectrin II (VS II)

Subscribe to Selected New Research on vasectrin II

68 relevant articles (2 outcomes, 1 trials/studies) found for this Bio-Agent

Description: analog of porcine secretin with sequence intermediate between secretin & vasoactive intestinal peptide (VIP); structure in first source

Also Known As:

VS II; 4-Ala-5-Val-secretin; secretin, Ala(4)-Val(5)-; secretin, alanyl(4)-valine(5)-; Secretin, 4-L-alanine-5-L-valine-

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 10/01/2003 - "Screen-detected and interval primary invasive breast cancers (n=685, screened) were more often smaller (P<0.0001), localised (P<0.0001) and histologically better differentiated (grade I vs II-III, P<0.0001) than pre-screening cancers and cancers detected after the defined interval from the last screening (n=184, clinical). " 07/01/2001 - "CONCLUSIONS: Among the prognostic predictors studied, only the status of the surgical resection margin (odds ratio, 5.7) and tumor stage (III and IV vs II showed odds ratios of 2.1 and 3.6, respectively) affected the prognosis for SCC of the mandibular region. " 01/01/2001 - "No correlation was found between p16 abnormalities and various clinicopathologic factors, including sex, histological type of tumor and TNM (I vs. II) stage. " 10/01/1999 - "In multivariate analysis, staging (Stage I vs. II and III) and tumor thickness were independent predictors of survival. " 01/01/1991 - "Significant differences were found both in the relation of the PgR concentration to different tumor stages (stage I vs. II-IV) and of the concentration to the different types of ploidy. " Order ALL the reference details at left...
2.	Neoplasm Metastasis (Metastasis) 09/01/2004 - "Multivariate analyses identified an earlier primary tumor stage (I vs II) (P<.001), an absence of intervening stage III metastases (P =.02), solitary metastasis (P<.001), and a long (>36 months) disease-free interval from AJCC stage I or II to stage IV (P =.005) as predictive of survival. " 11/01/2006 - "RESULTS: HD was confirmed in 4 out of 6 cell lines and in 8 out of 34 (23.5%) RCC specimens, which correlated with the presence of metastasis, high tumor grade and had a tendency to more advanced stage (I vs. II-IV). " 09/01/1999 - "Cyclin D1 overexpression is significantly higher in patients with lymph node metastasis (50.0% vs 14.4%, P = 0.002) and with advanced pathological stages (I, 10%; II, 53.8%; IIIa, 41.7%, P = 0.048; stage I vs II, IIIa, P = 0.006). " 01/15/1998 - "All 244 patients were subdivided into three groups described as follows: score 1 and 2, group I; score 3 and 4, group II; score 5 and 6, group III. In univariate analysis, lower score groups had better overall survival rate (OS), disease-free survival rate (DFS), local control rate (LC), and distant metastasis-free rate (DMF) than higher score groups including groups I vs. II, II vs. III, or I vs. III. The differences were all statistically significant except for the difference of the DMF in group I vs. II. In multivariate analysis, score (range 1-6) was also statistically significant in OS (p < 0.0001), DFS (p = 0.0015), LC (p = 0.0032), and DMF (p = 0.0141). " 06/15/1996 - "DNA ploidy heterogeneity was found in 67.7% of tumors and correlated with invasion depth (mucosa [40.5%] vs. submucosa-serosa [81.2%], P < 0.001), regional lymph node metastases (negative [58.4%] vs. positive [82.0%], P < 0.01), and stage grouping (I [58.8%] vs. II-IV [86.0%], P < 0.01). " Order ALL the reference details at left...
3.	Hypoglycemia (Reactive Hypoglycemia) 05/01/1993 - "During the final 2 h of hypoglycemia the incremental area under the curve (AUC) for glucagon was significantly greater in protocol I vs. II (3.0 +/- 1.0, -0.5 +/- 0.2 micrograms.l-1.min-1, P < 0.02, respectively). " Order ALL the reference details at left...
4.	Obstructive Sleep Apnea 01/01/1989 - "We observed nocturnal urinary protein excretion to be 16.2 +/- 5.5 micrograms/min (mean +/- SE) in 9 healthy control subjects (group I), 29.3 +/- 9.5 micrograms/min in 12 obese patients suspected to have obstructive sleep apnea syndrome (OSAS) but with negative polysomnographic studies (group II), and 94.0 +/- 31.8 micrograms/min in 14 patients with documented OSAS (group III) (II vs. I, NS; III vs. I, p less than 0.05; III vs. II, p less than 0.05). " Order ALL the reference details at left...
5.	Stroke (Strokes) 06/01/2007 - "RESULTS: The adjusted odds ratios for stroke for ID vs. II and DD vs. II were 0.837 (0.413-1.697) and 1.778 (0.596-5.300), respectively, for men; but were 1.700 (0.824-3.505) and 3.706 (1.375-9.985), respectively, for women. " 06/01/1999 - "Recovery of the maximal left ventricular stroke work index (LVSWImax) in Groups I vs II was 62.6+/-19.6% vs 73.3+/-23.3% (NS), maximal right ventricular stroke work index (RVSWImax) averaged 61.1+/-18.8 vs 87.8+/-31.7% (NS) as compared to the preoperative level. " 02/01/2006 - "Randomization is stratified by site, New York Heart Association (NYHA) heart class (I vs II-IV), and stroke or transient ischemic attack (TIA) within 1 year before randomization versus no stroke or TIA in that period. " 01/01/2005 - "Group I patients also had similar rates of paraplegia (I, 0% vs II, 2.2%), stroke (I, 1.2% vs II ,1.1%), and renal failure (I, 1.7% vs II, 5.5%). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Glucagon (Glukagon)
2.	vasectrin I (VS I)
3.	vasectrin III
4.	Cyclin D1
5.	Lactic Acid
6.	omega-N-Methylarginine (NG Monomethyl L Arginine)
7.	Leukocyte Elastase (Neutrophil Elastase)
8.	Interleukin-6 (Interleukin 6)
9.	Messenger RNA (mRNA)
10.	Pyridinolcarbamate (P23)

Related Therapies and Procedures

1.	Lymph Node Excision (Lymph Node Dissection)
2.	Transplants (Transplant)
3.	Renal Dialysis (Hemodialysis)
4.	Cardiopulmonary Bypass (Heart-Lung Bypass)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>